These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Risk of sulfonylurea drugs is underappreciated. Lin WH; Wright JM J Am Coll Cardiol; 2000 Mar; 35(3):820-1. PubMed ID: 10716492 [No Abstract] [Full Text] [Related]
3. Controversy about the relationship between sulfonylurea use and cardiovascular events and mortality. Shimoda M; Kaku K J Diabetes Investig; 2016 Sep; 7(5):674-6. PubMed ID: 27181105 [TBL] [Abstract][Full Text] [Related]
4. Possible risk of sulphonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease. Fasching P Diabetologia; 1998 Jun; 41(6):743-4. PubMed ID: 9662063 [No Abstract] [Full Text] [Related]
5. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. Garratt KN; Brady PA; Hassinger NL; Grill DE; Terzic A; Holmes DR J Am Coll Cardiol; 1999 Jan; 33(1):119-24. PubMed ID: 9935017 [TBL] [Abstract][Full Text] [Related]
6. Sulfonylureas and the risk of myocardial infarction. Thisted H; Johnsen SP; Rungby J Metabolism; 2006 May; 55(5 Suppl 1):S16-9. PubMed ID: 16631805 [TBL] [Abstract][Full Text] [Related]
7. Late complications of diabetes mellitus: risk factors in patients on sulfonylureas for more than 10 years. Hoshi M; Fujita S Jpn J Med; 1991; 30(6):616-7. PubMed ID: 1798228 [No Abstract] [Full Text] [Related]
8. Diabetes and coronary artery disease: time to stop taking the tablets. Edwards RJ; Rakhit RD; Marber MS Heart; 1999 Jun; 81(6):674. PubMed ID: 10979714 [No Abstract] [Full Text] [Related]
9. Does mortality risk vary among sulfonylureas? Pantalone KM Lancet Diabetes Endocrinol; 2015 Jan; 3(1):6-7. PubMed ID: 25466240 [No Abstract] [Full Text] [Related]
10. A comment on 'the risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy'. Chang Y; Choi NK; Hahn S; Park BJ Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1072-3; author reply 1073-4. PubMed ID: 17907252 [No Abstract] [Full Text] [Related]
11. Cardiovascular effects of diabetes drugs: emerging from the dark ages. Nissen SE Ann Intern Med; 2012 Nov; 157(9):671-2. PubMed ID: 23128866 [No Abstract] [Full Text] [Related]
12. Don't throw the baby out with the bath water: mortality with combination metformin and sulfonylurea. Tayek JA Diabetes Metab Res Rev; 2007 Feb; 23(2):85-6. PubMed ID: 17262894 [No Abstract] [Full Text] [Related]
13. Glimepiride-induced vasculitis: a case report. Ben Salem C; Hmouda H; Bouraoui K Br J Clin Pharmacol; 2007 Jul; 64(1):113-4. PubMed ID: 17324240 [No Abstract] [Full Text] [Related]
14. If not sulfonylureas, then what? Leibovitch ER Geriatrics; 2004 Sep; 59(9):47-8. PubMed ID: 15461239 [No Abstract] [Full Text] [Related]
15. [Hyperplastic skin reactions as the side effects of sulfonylurea preparations (the clinical manifestations and diagnosis)]. Potekaev NS; Kurdina MI Ter Arkh; 1992; 64(10):24-6. PubMed ID: 1485245 [No Abstract] [Full Text] [Related]
17. The UK Prospective Diabetes Study. Kerner W Lancet; 1998 Dec; 352(9144):1934. PubMed ID: 9863811 [No Abstract] [Full Text] [Related]
18. Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? Meier JJ; Gallwitz B; Schmidt WE; Mügge A; Nauck MA Heart; 2004 Jan; 90(1):9-12. PubMed ID: 14676228 [TBL] [Abstract][Full Text] [Related]
19. Summaries for patients. How do older diabetes drugs compare in their effects on heart and blood vessel disease? Ann Intern Med; 2012 Nov; 157(9):I-28. PubMed ID: 23128878 [No Abstract] [Full Text] [Related]
20. [Measures to meet the side effects of sulfonylurea (SU) in the treatment of type 2 diabetes]. Furukawa H; Ishida H Nihon Rinsho; 2002 Sep; 60 Suppl 9():357-61. PubMed ID: 12387018 [No Abstract] [Full Text] [Related] [Next] [New Search]